SGHTHealthcare · Medical DevicesSGHT Stock Forecast: Sight Sciences, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $8 — +44.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 1 Aug 2026 — in the upper half.
SGHT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Volatility (17): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership.
SGHT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +44.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | UBS | Assumes | Buy | $11 → $7.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $5.15 → $6.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Stifel | Maintains | Buy | — |
| 5 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 23 Dec 2025 | UBS | Maintains | Buy | — |
| 11 Dec 2025 | Citigroup | Maintains | Neutral | — |
| 10 Dec 2025 | Lake Street | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 21 Oct 2025 | Lake Street | Maintains | Buy | — |
| 7 Oct 2025 | Citigroup | Maintains | Neutral | — |
| 28 Aug 2025 | Needham | Reiterates | Hold | — |
| 21 Aug 2025 | Citigroup | Maintains | Neutral | — |
| 8 Aug 2025 | Lake Street | Upgrade | Buy | — |
| 15 July 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SGHT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Sight Sciences, Inc. (SGHT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −7.1×
- Price / sales
- 3.6×
- Price / book
- 5.3×
- EV / EBITDA
- −9.0×
Cheaper than 91% of US stocks
Cheaper than 35% of US stocks
Cheaper than 20% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- 12.5%
- Earnings growth (YoY)
- 12.5%
- Gross margin
- 86.2%
- Operating margin
- −35.6%
- Net margin
- −46.8%
Higher than 60% of US stocks
Higher than 53% of US stocks
Higher than 94% of US stocks
Higher than 20% of US stocks
Higher than 10% of US stocks
- Return on equity
- −56.6%
- Return on assets
- −14.3%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SGHT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGHT appears on the weeks it earns a place.
Frequently asked questions about SGHT stock
What is the SGHT stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SGHT stock a buy right now?
Of the 7 analysts covering Sight Sciences, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 67 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SGHT?
As at 1 Aug 2026, Sight Sciences, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
Will SGHT stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +44.7% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 67 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SGHT stock forecast for 2030?
No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
How has SGHT stock performed over the past year?
Sight Sciences, Inc. returned +69.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sight Sciences, Inc. do?
Sight Sciences Inc. is a company specializing in medical technology aimed at addressing eye diseases.
About Sight Sciences, Inc.
Sight Sciences Inc. is a company specializing in medical technology aimed at addressing eye diseases. The primary function of the company is to develop and commercialize innovative ophthalmic products, particularly for conditions such as glaucoma and dry eye syndrome. Their notable technologies include the OMNI Surgical System, which is designed to address the full range of outflow pathways involved in glaucoma treatment, and the TearCare System for more efficient treatment of evaporative dry eye. Sight Sciences Inc. plays a vital role in the healthcare sector, particularly in the field of ophthalmology, and is driven by a mission to transform eye care through highly effective and minimally invasive solutions. By focusing on underserved patient populations, the company not only impacts individual patient outcomes but also contributes to advancing the standards of eye disease management globally. With its headquarters in the United States, Sight Sciences is part of the broader medical technology community that continues to innovate in pursuit of better health outcomes.
CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com